Inulin propionate ester, cleared by the EU's food safety regulator EFSA as a novel food ingredient, ferments in the gut to release the appetite suppressing hormone GLP 1.
Europe has a new official answer to a question readers keep asking: can ordinary food mimic what Ozempic does to appetite? The answer, sitting in the EU's novel-food register, is a chemically tuned dietary fibre called inulin-propionate ester, or IPE. EFSA, the European Food Safety Authority, signed off on it as safe earlier this year, and food companies are already lining up breads, smoothies and cereals built around it.
The mechanism is the same one that makes semaglutide, sold as Ozempic and Wegovy, so effective at suppressing appetite. Gut bacteria ferment ordinary dietary fibre in the colon into short-chain fatty acids, principally acetate, propionate and butyrate. IPE is engineered to deliver an outsized dose of propionate at a much smaller serving of fibre. Propionate then signals enteroendocrine cells in the gut wall to release GLP-1 and PYY, the same appetite-suppressing hormones that GLP-1 agonist drugs mimic directly. The keyword is "mimic at a fraction of the potency": food triggers a hormone release, while drugs deliver a sustained pharmacological dose of a GLP-1 analogue.
The clinical evidence is modest. A randomised controlled trial led by Gary Frost at Imperial College London tested 10 grams of IPE a day in adults aged 40 to 65 over six months. The treatment group did not lose weight; they were simply less likely to gain it. Seventeen per cent of the control group gained more than one per cent of their body weight, against a much smaller share on IPE. A second, larger trial followed 270 younger adults, ages 20 to 40, for a year. Total body weight did not move, but body composition shifted toward higher lean mass and lower fat mass on IPE. The drug comparison journalists keep reaching for is the wrong comparison. IPE is a food ingredient with a food-sized hormonal nudge, not a non-drug route to the dramatic results of GLP-1 agonists.
The dose matters here too. To get a comparable propionate effect from ordinary inulin or other fermentable fibre, a person would have to eat roughly 80 grams of fibre a day. Most adults manage closer to 20. IPE packages the propionate payload into something close to a couple of teaspoons, which is why food manufacturers see a real product story rather than a "just eat more bran" lecture. The trade-off, visible in trial reports, is gastrointestinal: more flatulence than the placebo arm reported, because propionate fermentation is still propionate fermentation.
Regulatorily, the trail runs through EFSA's safety opinion, published in the EFSA Journal under publication 9534 in 2025, and the EU's novel food framework under Regulation 2015/2283. The European Commission maintains the Union List of Novel Foods, where IPE will need an implementing amendment before it can appear on EU shelves, and the applicant dossier on inulin-propionate ester sits in DG SANTE's documents register. New Scientist's framing article is useful for the consumer-facing read, but the load-bearing authority is EFSA and the Commission record, not the magazine write-up.
What to watch next is straightforward. Industry and supplier projections cited in the trade press put the first IPE-containing products, breads, smoothies and cereals, on European shelves within roughly a year of approval. That would be the first real-world test of whether people will keep eating 10 grams of a propionate-delivering fibre every day and whether the modest weight-gain prevention seen in middle-aged trial volunteers holds up outside a controlled feeding study. The bigger unresolved question is whether the GLP-1 and PYY nudge stays strong enough to matter when IPE is one ingredient among many in a processed loaf, or whether the effect fades the moment a product stops tasting like the trial supplement.